Oz Azam has operated at the intersection of science, capital, and execution for more than 24 years, and he has done it across some of the most complex environments in the industry. As Global Head of Cell & Gene Therapies at Novartis, he sat on the Pharmaceutical Executive Committee and led a $500M+ organization across four global locations, building the infrastructure that brought CAR-T and HSC therapies to commercial scale. He then founded and led Tmunity Therapeutics, raising $231 million, delivering three novel first-in-man INDs, and completing the sale of a GMP manufacturing facility to Resilience before Tmunity was acquired by Kite (Gilead). He went on to lead Empyrean Neuroscience, advancing the world's first genetically engineered psilocybin drug product toward the clinic, before taking the helm at Cue Biopharma, where he now serves as Chief Executive Officer. From Novartis boardrooms to serial company formation, Oz brings a rare combination of institutional scale and founder-level grit and a track record of seeing programs through from concept to clinical stage.

Howard Berman builds companies — and then takes on the next challenge before the ink is dry. He founded and led Coya Therapeutics from inception through its Nasdaq IPO in a bare market, secured a transformative $700 million licensing deal, and has raised over $100 million across private, public, and non-dilutive rounds. He simultaneously serves as CEO and Chairman of ReAlta Life Sciences, a clinical-stage biopharmaceutical company developing first-in-class peptides for devastating inflammation-driven diseases, and sits on the boards of Atea Pharmaceuticals (Nasdaq) and Mammogen, a precision diagnostics company focused on earlier breast cancer detection. His drug development credentials span the launch of blockbuster medicines including Focalin XR, Alimta, Monjuvi, and Venetoclax — across oncology, neurodegeneration, and CNS. A PhD in Neuropharmacology from Weill Cornell, a PharmaVoice 100 winner, and a Scrip Awards finalist for Executive of the Year, Howard operates simultaneously across multiple boards and C-suites — and brings the full arc of biotech leadership to every engagement.

Dan Bloomfield is an Oxford Rhodes Scholar, a Fellow of the American College of Cardiology and the American Heart Association, and one of the most experienced cardiovascular drug developers in the industry. He spent eight years on the faculty of Columbia University as an academic cardiologist before joining Merck, where he rose over 12 years to become Senior Vice President of Global Clinical Development and Therapeutic Area Head for Cardiovascular Disease — overseeing programs including Januvia, Zetia/Vytorin, and a 30,000-patient outcomes trial run in partnership with Oxford and Harvard. During that tenure he also served as Chief of Staff to Merck CEO Kenneth Frazier, gaining enterprise-wide exposure to corporate governance, investor relations, and global strategy. He was appointed MRL Lead for China R&D, overseeing a team of approximately 450 people across all therapeutic areas. In 2017 he became the founding CEO of Cardurion Pharmaceuticals, building the company from the ground up around novel heart failure programs before transitioning to CMO and Board Director. He co-founded the Cardiac Safety Research Consortium, a public-private FDA partnership that has shaped regulatory guidance on cardiac safety in drug development, and served as Rapporteur on the ICH E14 Implementation Working Group for nearly eight years. He currently serves as CMO of Anthos Therapeutics — a Blackstone Life Sciences and Novartis-backed company — leading development of a next-generation anti-thrombotic with the potential to prevent multiple thrombotic diseases with minimal bleeding risk. Dan brings the scientific rigour of academia, the institutional depth of big pharma, and the conviction of a founder.

Greg Fiore has built things — and then built the next thing. A clinical fellow at Harvard Medical School, valedictorian of his medical school class, and former McKinsey consultant, he co-founded SSI Strategy in 2011 and grew it to a team of 50+ physicians, scientists, and management consultants before its private equity-backed acquisition in 2020. He went on to found Fiore Healthcare Advisors, scaling it to nearly $10 million in annual revenues before that too was acquired. He then co-founded and led Exacis Biotherapeutics, an immuno-oncology company leveraging mRNA technologies for engineered iPSC-derived NK cell therapies, which was acquired by a public biotech in 2023. Earlier in his career, he served as Chief Medical Officer at The Medicines Company — later acquired by Novartis — and as North America Regional Head of Global Pharmacovigilance at Merck, leading a team of over 100 safety professionals. Through GJFMD Consulting, he now provides medical, scientific, and strategic counsel to early and mid-stage pharmaceutical and biotech companies. Greg has founded companies, led them through acquisition, and sat on the boards of the next generation of biotechs. He knows what it takes from every seat at the table.

Ilan Ganot's path into biotech is unlike anyone else's in this network — and that is precisely what makes his perspective valuable. He spent a decade as an investment banker at JPMorgan, Nomura, and Lehman Brothers across London, Hong Kong, and New York before co-founding Solid Biosciences in 2013 — a company born from personal conviction, built around Duchenne muscular dystrophy, and taken public on Nasdaq. He led Solid as CEO for nearly a decade. He now serves as CEO of Alesta Therapeutics, focused on rare disease small molecule development, and sits on the boards of Solid Biosciences and Minovia Therapeutics. Ilan holds an MBA from London Business School, practiced corporate law in Israel, and served as a Captain in the Israeli Defense Forces. He sees capital, science, and governance through lenses most executives never develop simultaneously.

Fred Grossman has spent more than 25 years at the centre of CNS drug development — not on the periphery, but leading the programs that defined the field. His fingerprints are on the clinical development and lifecycle management of some of the most prescribed medicines in psychiatry and neuroscience: Cymbalta, Risperdal, Risperdal Consta, Invega, Abilify, and Latuda. He has held senior executive positions at Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, and Sunovion, leading global clinical development, medical affairs, and pharmacovigilance across teams of up to 500 professionals and budgets exceeding $350 million. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals, overseeing the company's first NDA approval, and as CMO at Mesoblast, developing allogeneic stem cell therapies in Phase 3 for conditions including acute graft-versus-host disease and chronic heart failure. Board-certified in Psychiatry and a Fellow of the American Psychiatric Association, he was also a Fellow at the National Institutes of Health. He now serves as President and CMO at Coya Therapeutics, where he is advancing a novel immunotherapy approach targeting regulatory T cells for neurodegenerative diseases including ALS, Alzheimer's, and Parkinson's. Fred brings the institutional depth of big pharma and the conviction of someone who has chosen, repeatedly, to apply that depth to the hardest problems in medicine.

Chris Morabito began his career where medicine is at its most urgent — as a neonatologist and paediatric critical care physician at UCSF and Lehigh Valley Health Network, caring for critically ill neonates and children with life-threatening cardiovascular, respiratory, and neurological disorders. He brought that clinical foundation into the pharmaceutical industry at Merck, where he led global clinical development in cardiovascular disease, and then at Sanofi, where he served as Global Project Head across diabetes and infectious disease programmes. At Takeda, he rose to lead cross-therapeutic area portfolio strategy across oncology, GI, and neuroscience — and was then asked to lead R&D integration following Takeda's $62 billion acquisition of Shire, one of the largest pharmaceutical deals in history. He established the blueprint for Takeda's post-acquisition R&D organisation and represented R&D to the investor community throughout the process. He went on to serve as CMO at Cardurion Pharmaceuticals, Fulcrum Therapeutics, and Astria Therapeutics, building a track record across rare disease, cardiovascular, and immunological programmes. Chris brings a perspective shaped by the full arc of medicine — from the bedside to the boardroom, from early development to late-stage regulatory strategy.

Sukumar Nagendran oversaw the development of Zolgensma — the first one-time systemic gene therapy approved in the United States. That milestone alone places him in a category few can claim. With more than 30 years leading clinical development, medical affairs, and regulatory strategy across gene therapy, rare disease, and diagnostics, he has held CMO and R&D leadership roles at AveXis, Jaguar Gene Therapy, Quest Diagnostics, Pfizer, Novartis, and Daiichi Sankyo. He currently serves as President and Head of R&D at Taysha Gene Therapies and sits on the boards of Solid Biosciences, Amlogenyx, and others. A Mayo Alumni Laureate and founding member of the Robert Wood Johnson Legacy Society, Sukumar brings the kind of regulatory and development depth that only comes from having navigated the hardest approvals in the industry.

Sharief Taraman is the CEO of Cognoa, the company behind Canvas Dx — the first and only FDA-authorised AI-powered diagnostic for autism in children aged 18 months to six years. He joined Cognoa as Vice President of Medical in 2017, became Chief Medical Officer in 2018, and was appointed CEO in 2022, growing through every level of the organization before taking the top seat. Dual board-certified in Neurology (with special qualifications in Child Neurology) and Clinical Informatics, he has spent more than 14 years as an Attending Physician and Physician Informaticist at CHOC Children's Hospital, where he served as Division Chief of Pediatric Neurology and co-founded the MI4 Institute's summer internship programme. He is a co-inventor of Move-D, a first-of-its-kind mechanical brace for paediatric tremor disorders developed in collaboration with UC Irvine. He has served as a member of the California Surgeon General's Perinatal Advisory Group, President of the American Academy of Pediatrics Orange County Chapter, and holds faculty appointments at UC Irvine, UC Riverside, and Chapman University's School of Engineering. Before entering digital health, he developed monoclonal antibodies at Pfizer and served as Principal Investigator on FDA registrational trials. Sharief is a clinician, an inventor, an informaticist, and a CEO  and he has built each of those identities in parallel, not in sequence.

James Wooldridge has spent more than 25 years doing the work most advisors only theorise about — guiding drug programs from pre-IND through Phase 3, running first-in-human studies, and navigating the regulatory interactions that define whether a molecule becomes a medicine. He has been instrumental in the clinical development of approximately 20 compounds, including 10 first-in-human programs and one drug approved in Europe. At Immunitas Therapeutics, where he currently serves as Chief Medical Officer, he leads pipeline development while staying actively engaged in investor relations and fundraising. He has contributed to major financings, supported a successful IPO, and been through an acquisition. He has authored or co-authored more than 40 scientific publications. When a clinical program needs a reset — or a board needs someone who has genuinely been there — James has the track record to back it.